JP7132233B2 - 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法 - Google Patents

全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法 Download PDF

Info

Publication number
JP7132233B2
JP7132233B2 JP2019546767A JP2019546767A JP7132233B2 JP 7132233 B2 JP7132233 B2 JP 7132233B2 JP 2019546767 A JP2019546767 A JP 2019546767A JP 2019546767 A JP2019546767 A JP 2019546767A JP 7132233 B2 JP7132233 B2 JP 7132233B2
Authority
JP
Japan
Prior art keywords
biomarkers
kit
sjia
subject
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502541A5 (https=
JP2020502541A (ja
Inventor
パトリシア ベックマン，
リンジー ラザフォード，
アンナ デイリー，
オミード モガダム，
エリザベス メリンズ，
Original Assignee
アセンダント ディーエックス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセンダント ディーエックス， エルエルシー filed Critical アセンダント ディーエックス， エルエルシー
Publication of JP2020502541A publication Critical patent/JP2020502541A/ja
Publication of JP2020502541A5 publication Critical patent/JP2020502541A5/ja
Priority to JP2022084414A priority Critical patent/JP2022110148A/ja
Application granted granted Critical
Publication of JP7132233B2 publication Critical patent/JP7132233B2/ja
Priority to JP2024098692A priority patent/JP2024120022A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
JP2019546767A 2016-11-11 2017-11-10 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法 Active JP7132233B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022084414A JP2022110148A (ja) 2016-11-11 2022-05-24 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP2024098692A JP2024120022A (ja) 2016-11-11 2024-06-19 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420991P 2016-11-11 2016-11-11
US62/420,991 2016-11-11
PCT/US2017/061057 WO2018089764A1 (en) 2016-11-11 2017-11-10 Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and kawasaki disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084414A Division JP2022110148A (ja) 2016-11-11 2022-05-24 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020502541A JP2020502541A (ja) 2020-01-23
JP2020502541A5 JP2020502541A5 (https=) 2020-10-22
JP7132233B2 true JP7132233B2 (ja) 2022-09-06

Family

ID=62110362

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019546767A Active JP7132233B2 (ja) 2016-11-11 2017-11-10 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP2022084414A Withdrawn JP2022110148A (ja) 2016-11-11 2022-05-24 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP2024098692A Pending JP2024120022A (ja) 2016-11-11 2024-06-19 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022084414A Withdrawn JP2022110148A (ja) 2016-11-11 2022-05-24 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP2024098692A Pending JP2024120022A (ja) 2016-11-11 2024-06-19 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法

Country Status (4)

Country Link
US (1) US11448648B2 (https=)
EP (1) EP3529596B1 (https=)
JP (3) JP7132233B2 (https=)
WO (1) WO2018089764A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113252806B (zh) * 2021-03-25 2023-08-29 嘉兴学院 S-腺苷同型半胱氨酸在制备用于诊断或治疗川崎病的产品中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045507A1 (en) 2008-01-29 2011-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fstl-1 as a biomaker of inflammation
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
US20130052665A1 (en) 2011-08-25 2013-02-28 Bruce Xuefeng Ling Methods for diagnosis of systemic juvenile idiopathic arthritis
JP2015505245A (ja) 2011-12-29 2015-02-19 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 川崎病のためのバイオマーカー

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
WO1993003151A1 (en) 1991-08-10 1993-02-18 Medical Research Council Treatment of cell populations
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
DE69638321D1 (de) 1995-10-11 2011-03-03 Luminex Corp Gleichzeitige mehrfachanalyse klinischer proben
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999019515A1 (en) 1997-10-14 1999-04-22 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
AU3463699A (en) 1998-04-03 1999-10-25 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
WO2013167727A2 (en) 2012-05-11 2013-11-14 Westfaelische Wilhelms-Universitaet Muenster Method for determining arthritis relapse risk

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045507A1 (en) 2008-01-29 2011-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fstl-1 as a biomaker of inflammation
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
US20130052665A1 (en) 2011-08-25 2013-02-28 Bruce Xuefeng Ling Methods for diagnosis of systemic juvenile idiopathic arthritis
JP2015505245A (ja) 2011-12-29 2015-02-19 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 川崎病のためのバイオマーカー

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
David C Wilson，Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis，Arthritis Rheum，2010年08月，Vol.62 No.8，Page.2510-2516
Frosch M，The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis，Arthritis Rheum，2009年03月，Vol.60 No.3，Page.883-891
Gorelik M，Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis，J Rheumatol，2013年05月15日，Vol.40 No.7，Page.1191-1199
Guo Q，Serum calprotectin-a promising diagnostic marker for adult-onset Still's disease，Clin Rheumatol，2015年11月07日，Vol.35 No.1，Page.73-79
Susan Shenoi，Comparison of biomarkers for systemic juvenile idiopathic arthritis，Pediatr Res，2015年08月12日，Vol.78 No.5，Page.554-559
Xuefeng B. Ling，Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications，Proteomics，2010年12月，Vol.10 No.24，Page.4415-4430

Also Published As

Publication number Publication date
US11448648B2 (en) 2022-09-20
US20190293644A1 (en) 2019-09-26
EP3529596A1 (en) 2019-08-28
EP3529596C0 (en) 2025-08-13
JP2024120022A (ja) 2024-09-03
JP2020502541A (ja) 2020-01-23
EP3529596A4 (en) 2020-05-13
WO2018089764A1 (en) 2018-05-17
EP3529596B1 (en) 2025-08-13
JP2022110148A (ja) 2022-07-28

Similar Documents

Publication Publication Date Title
TWI708058B (zh) 阿茲海默症及其他神經退化性疾病之生物標記及診斷方法
CN107110867B (zh) 用于肝癌诊断的生物标记物及其用途
US20050064516A1 (en) Biological markers for diagnosing multiple sclerosis
JP2021036233A (ja) バイオマーカーとしての遊離ヒストンタンパク質
EP3497450B1 (en) Histones and/or proadm as markers indicating organ dysfunction
US20150377905A1 (en) Methods for diagnosis of kawasaki disease
US20140236166A1 (en) Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts
WO2007082586A1 (en) Method and markers for the diagnosis of renal diseases
US20170052200A1 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
JP2010534341A (ja) 早産の危険性を評価するためのバイオマーカーの同定および定量化
Bergman et al. Recent developments in proteomic methods and disease biomarkers
KR101390590B1 (ko) 췌장암 재발 예후 예측용 마커 및 이의 용도
KR101390543B1 (ko) 췌장암 진단용 마커 및 이의 용도
JP2024120022A (ja) 全身型若年性特発性関節炎および川崎病を診断および識別するための組成物および方法
JP2009500641A (ja) 多発性硬化症の診断方法
US20170097352A1 (en) Immunoglobulin-bound extracellular vesicles and uses thereof
US20060286602A1 (en) Method and markers for the diagnosis of renal diseases
KR101859812B1 (ko) 간암 화학 색전술 치료 예후 예측을 위한 바이오마커 및 그 용도
KR102131860B1 (ko) 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
HK40012520B (en) Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and kawasaki disease
HK40012520A (en) Compositions and methods for diagnosing and differentiating systemic juvenile idiopathic arthritis and kawasaki disease
US20160018415A1 (en) Marker for diagnosing diabetic retinopathy and use therof
US12092640B2 (en) Methods and compositions for diagnosis of rickettsia infection
US20190317091A1 (en) Method of early diagnosis of immune-mediated inflammatory disease
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220825

R150 Certificate of patent or registration of utility model

Ref document number: 7132233

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250